EUCTR2004-001473-25-GB进行中（未招募）不适用
A facilitated access program to provide Everolimus (RAD) for maintenance for patients completing therapy in RAD trials in solid organ transplantation.
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 1,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Subject is currently enrolled in an everolimus (RAD) trial sponsored by Novartis
- •2. Currently on everolimus (RAD) therapy.
- •3. Male or female recipients of a solid organ transplant.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Inability or unwillingness to comply with immunosuppressive regimen.
- •2. Pregnancy.
- •3. History of acute organ rejection within the last 3 months. These patients may be screened again when they have been without rejection for greater than 3 months.
研究者
相似试验
进行中（未招募）
1 期
A facilitated access program to provide Everolimus (RAD) for maintenance for patients completing therapy in RAD trials in solid organ transplantation. - The umbrella protocolEUCTR2004-001473-25-BEovartis Pharmaceuticals Corporation1,000
No Longer Available
不适用
A Facilitated Access Program to Provide Everolimus (RAD) Maintenance for Patients Completing Therapy in RAD Trials in Solid Organ TransplantationOrgan TransplantationNCT00149981Novartis Pharmaceuticals
已完成
不适用
Expanded Access Program to provide Nusinersen to Patients with infantile-onset spinal muscular atrophy (SMA)G12.0Infantile spinal muscular atrophy, type I [Werdnig-Hoffman]DRKS00011547Klinik für Neuropädiatrie und MuskelerkrankungenZentrum für Kinder- und JugendmedizinUniversitätsklinikum Freiburg61
尚未招募
不适用
EXPANDED ACCESS PROGRAM WITH NIVOLUMAB FOR SUBJECTS WITH HISTOLOGICALLY CONFIRMED STAGE III (UNRESECTABLE) OR STAGE IV MELANOMA PROGRESSING POST PRIOR SYSTEMIC TREATMENT CONTAINING AN ANT-CTLA-4 MONOCLONAL ANTIBODY.-C439 Malignant melanoma of skin, unspecifiedMalignant melanoma of skin, unspecifiedC439PER-012-15BRISTOL MYERS SQUIBB COMPANY,
进行中（未招募）
1 期
Program to allow continuation of treatment with Entyvio (Vedolizumab IV) for patients with ulcerative colitis and Chron´s disease who previously participated in a clinical trial with this same treatmentlcerative Colitis and Crohn’s DiseaseMedDRA version: 20.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856MedDRA version: 20.0Level: LLTClassification code 10013099Term: Disease CrohnsSystem Organ Class: 100000004856EUCTR2016-000678-40-HUTakeda Development Centre Europe Limited385